Literature DB >> 27798227

Cell death mechanisms in human chronic liver diseases: a far cry from clinical applicability.

Guillermo Mazzolini1,2, Jan-Peter Sowa1, Ali Canbay3.   

Abstract

The liver is constantly exposed to a host of injurious stimuli. This results in hepatocellular death mainly by apoptosis and necrosis, but also due to autophagy, necroptosis, pyroptosis and in some cases by an intricately balanced combination thereof. Overwhelming and continuous cell death in the liver leads to inflammation, fibrosis, cirrhosis, and eventually hepatocellular carcinoma. Although data from various disease models may suggest a specific (predominant) cell death mode for different aetiologies, the clinical reality is not as clear cut. Reliable and non-invasive cell death markers are not available in general practice and assessment of cell death mode to absolute certainty from liver biopsies does not seem feasible, yet. Various aetiologies probably induce different predominant cell death modes within the liver, although the death modes involved may change during disease progression. Moreover, current methods applicable in patients are limited to surrogate markers for apoptosis (M30), and possibly for pyroptosis (IL-1 family) and necro(pto)sis (HMGB1). Although markers for some death modes are not available at all (autophagy), others may not be specific for a cell death mode or might not always definitely indicate dying cells. Physicians need to take care in asserting the presence of cell death. Still the serum-derived markers are valuable tools to assess severity of chronic liver diseases. This review gives a short overview of known hepatocellular cell death modes in various aetiologies of chronic liver disease. Also the limitations of current knowledge in human settings and utilization of surrogate markers for disease assessment are summarized.
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  apoptosis; chronic liver disease; necroptosis; necrosis.

Mesh:

Year:  2016        PMID: 27798227     DOI: 10.1042/CS20160035

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  11 in total

1.  Pyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications.

Authors:  Juliane I Beier; Jesus M Banales
Journal:  J Hepatol       Date:  2018-02-14       Impact factor: 25.083

Review 2.  Apoptosis and necroptosis in the liver: a matter of life and death.

Authors:  Robert F Schwabe; Tom Luedde
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-12       Impact factor: 46.802

3.  High Circulating Caspase-Cleaved Keratin 18 Fragments (M30) Indicate Short-Term Mortality in Critically Ill Patients.

Authors:  Alexander Koch; Eray Yagmur; Janine Linka; Fabienne Schumacher; Jan Bruensing; Lukas Buendgens; Ulf Herbers; Ger H Koek; Ralf Weiskirchen; Christian Trautwein; Frank Tacke
Journal:  Dis Markers       Date:  2018-07-08       Impact factor: 3.434

Review 4.  Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies.

Authors:  Jens U Marquardt; Frank Edlich
Journal:  Front Oncol       Date:  2019-12-13       Impact factor: 6.244

Review 5.  Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence.

Authors:  Guillermo Mazzolini; Jan-Peter Sowa; Catalina Atorrasagasti; Özlem Kücükoglu; Wing-Kin Syn; Ali Canbay
Journal:  Cells       Date:  2020-11-11       Impact factor: 6.600

6.  Necroptosis Underlies Hepatic Damage in a Piglet Model of Lipopolysaccharide-Induced Sepsis.

Authors:  Qiao Xu; Junjie Guo; Xiangen Li; Yang Wang; Dan Wang; Kan Xiao; Huiling Zhu; Xiuying Wang; Chien-An Andy Hu; Guolong Zhang; Yulan Liu
Journal:  Front Immunol       Date:  2021-03-12       Impact factor: 7.561

7.  Association of cell death mechanisms and fibrosis in visceral white adipose tissue with pathological alterations in the liver of morbidly obese patients with NAFLD.

Authors:  Anna-Sophia Leven; Robert K Gieseler; Martin Schlattjan; Thomas Schreiter; Marco Niedergethmann; Theodor Baars; Hideo A Baba; Mustafa K Özçürümez; Jan-Peter Sowa; Ali Canbay
Journal:  Adipocyte       Date:  2021-12       Impact factor: 4.534

8.  Sinapic Acid Reduces Oxidative Stress and Pyroptosis via Inhibition of BRD4 in Alcoholic Liver Disease.

Authors:  Junyi Chu; Ran Yan; Sai Wang; Guoyang Li; Xiaohui Kang; Yan Hu; Musen Lin; Wen Shan; Yan Zhao; Zhecheng Wang; Ruimin Sun; Jihong Yao; Ning Zhang
Journal:  Front Pharmacol       Date:  2021-06-04       Impact factor: 5.810

9.  SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease.

Authors:  Guillermo Mazzolini; Catalina Atorrasagasti; Agostina Onorato; Estanislao Peixoto; Martin Schlattjan; Jan-Peter Sowa; Svenja Sydor; Guido Gerken; Ali Canbay
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

10.  Hypothermic oxygenated machine perfusion (HOPE) for orthotopic liver transplantation of human liver allografts from extended criteria donors (ECD) in donation after brain death (DBD): a prospective multicentre randomised controlled trial (HOPE ECD-DBD).

Authors:  Zoltan Czigany; Wenzel Schöning; Tom Florian Ulmer; Jan Bednarsch; Iakovos Amygdalos; Thorsten Cramer; Xavier Rogiers; Irinel Popescu; Florin Botea; Jiří Froněk; Daniela Kroy; Alexander Koch; Frank Tacke; Christian Trautwein; Rene H Tolba; Marc Hein; Ger H Koek; Cornelis H C Dejong; Ulf Peter Neumann; Georg Lurje
Journal:  BMJ Open       Date:  2017-10-10       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.